Jared Wolff is an Analyst at CBPartners.
Connect with Jared Louis Wolff
Basic science has been redeployed to establish a new understanding of Alzheimer's Disease, focusing on novel biomarkers and cutting-edge therapeutic approaches to slow or reverse disease progression, where the amyloid beta theory has otherwise failed
The final episode of the COVID-19 trilogy focuses on testing. Specifically, the different types of tests available for COVID-19 and the regulatory environment in which these tests exist.
Patent management is the hot topic of this episode. The focus is on AMARIN’s leading product, VASCEPA, a drug made up of natural derivatives such as fish oil and was approved by the FDA in December 2019.
In Part 2 of the COVID-19 series, healthcare consultant Jared Wolff is again joined by Matthew Rube and Akhil Parlapalli from CBPartners’ New York office to discuss some of the most promising treatments that are currently being put to the test against COVID-19.
In this episode, our host Jared Wolff is joined by healthcare consultants Sophie Katz (a core member of CBPartners' Cell and Gene Therapy Center of Excellence), and Jay Galli to discuss some interesting topics surrounding cell and gene therapies.
In this episode, Jared Wolff is joined by Matthew Rube and Akhil Parlapalli from CBPartners' New York office to discuss some of the topics surrounding the novel coronavirus (COVID-19) pandemic: